| Drug Name |
Linagliptin |
| Drug ID |
BADD_D01292 |
| Description |
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557]. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050]. Linagliptin was approved by the FDA on May 2, 2011[L9557]. |
| Indications and Usage |
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise[L9557]. It should not be used to treat type I diabetes or in diabetic ketoacidosis.[L9557] An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.[L11479] |
| Marketing Status |
approved |
| ATC Code |
A10BH05 |
| DrugBank ID |
DB08882
|
| KEGG ID |
D09566
|
| MeSH ID |
D000069476
|
| PubChem ID |
10096344
|
| TTD Drug ID |
D02EYG
|
| NDC Product Code |
12714-153; 62993-0808; 65862-970; 0597-0140; 64220-184; 55154-0410; 65015-854; 53104-7701; 63415-0521; 66039-908; 73309-391; 50370-0045; 69037-0008; 65727-057; 51869-0020; 55111-972 |
| UNII |
3X29ZEJ4R2
|
| Synonyms |
Linagliptin | (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione | 1H-purine-2,6-dione, 8-((3r)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)- | BI 1356 | 1356, BI | BI1356 | BI-1356 | Tradjenta | Trajenta |
